secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cocrystal Pharma, Inc. (COCP)
CIK:        0001412486
Form:       8-K
Filed at:   2024-11-13T23:59:59+00:00
Accession:  0001493152-24-045083
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cocrystal Pharma Q3 net loss $4.9M; cash $13M; expects topline data from two studies soon
--------------------------------------------------------------------------------

- Net loss Q3 2024 of $4.9M ($0.49 per share) vs $4.2M ($0.41) in Q3 2023 which included $1.6M legal settlement.
- Cash and cash equivalents $13.0M as of Sep 30, 2024, down from $26.4M at Dec 31, 2023; working capital $12.3M.
- R&D expenses $3.2M (down from $4.2M); G&A $1.8M (stable).
- Expects topline results from Phase 2a influenza A challenge study (CC-42344) by year end 2024.
- Topline results from Phase 1 norovirus/coronavirus study (CDI-988) expected late 2024/early 2025; cash sufficient for 12 months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1412486/000149315224045083/0001493152-24-045083-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1412486/000149315224045083/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-045083

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer